Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

Naive T cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers

(2019) Rajat K Das et al.   Cancer Discovery

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

(2019) Nirav N. Shah et al.   Frontiers in Oncology

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

(2019) Eric L. Smith et al.   Science Translational Medicine

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells

(2019) Alexandre V. Hirayama et al.   BLOOD

Chimeric antigen receptor T cell persistence and memory cell formation

(2019) Alexander D McLellan et al.   IMMUNOLOGY AND CELL BIOLOGY

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

(2019) Cesar Sommer et al.   MOLECULAR THERAPY

Evolution of CAR T-cell immunotherapy in terms of patenting activity

(2019) Björn Jürgens et al.   NATURE BIOTECHNOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype

(2018) Saisai Li et al.   HUMAN GENE THERAPY

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

(2018) Eric L. Smith et al.   MOLECULAR THERAPY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

(2018) John K. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Strategies to Address Chimeric Antigen Receptor Tonic Signaling

(2018) Adam Ajina et al.   MOLECULAR CANCER THERAPEUTICS

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD38 as an immunotherapeutic target in multiple myeloma

(2018) Francesca Bonello et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Universal CARs, universal T cells, and universal CAR T cells

(2018) Juanjuan Zhao et al.   Journal of Hematology & Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Making CAR T Cells a Solid Option for Solid Tumors

(2018) Andrea Schmidts et al.   Frontiers in Immunology

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Stefania Oliva et al.   Frontiers in Immunology

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

T memory stem cells in health and disease

(2017) Luca Gattinoni et al.   NATURE MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Novel Immunotherapies for Multiple Myeloma

(2017) Mattia D’Agostino et al.   Current Hematologic Malignancy Reports

T-cell receptor-engineered T cells for cancer treatment: current status and future directions

(2017) Yu Ping et al.   Protein & Cell

Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy

(2016) Oladapo O. Yeku et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview

(2016) C. H. J. Lamers et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

Multiple myeloma epidemiology and survival: A unique malignancy

(2016) Dickran Kazandjian   SEMINARS IN ONCOLOGY

Classification of current anticancer immunotherapies

(2015) Lorenzo Galluzzi et al.   Oncotarget

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

(2013) R. O. Carpenter et al.   CLINICAL CANCER RESEARCH

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors

(2012) N. Cieri et al.   BLOOD

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA